Faculty Disclosures

All relevant financial relationships have been mitigated.

Presenter Disclosures

• Katelyn Atkins, MD, PhD, is employed by Cedars-Sinai Medical Center. Dr. Atkins receives grant/research funding from Varian Medical Systems. 
• Christopher A. Barker, MD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Barker receives grant/research funding from EMD Serono, Elekta and Regeneron.  
• Jose Bazan, MD, MS, is employed by City of Hope and has no relevant financial relationships to disclose.
• Ralph Ermoian, MD, is employed by the University of Washington and has no relevant financial relationships to disclose. 
• B. Ashleigh Guadagnolo, MD, FASTRO, MPH, is employed by MD Anderson Cancer Center and has no relevant financial relationships to disclose.
• Lauren Henke, MD, MS, is employed by University Hospitals. Dr. Henke receives grant/research funding from Varian Medical Systems and receives compensation/payment from Elekta.
• Kimberly Johung, MD, PhD, is employed by Yale University School of Medicine and has no relevant financial relationships to disclose. 
• Michelle Kim, MD, is employed by University of Michigan and has no relevant financial relationships to disclose. 
• Amar Kishan, MD, is employed by UCLA. Dr. Kishan receives honoraria from Varian Medical Systems and Boston Scientific. Dr. Kishan receives grant/research funding from Janssen, Inc., Point BioPharma, Lantheus, Novartis and ViewRay Systems. Dr. Kishan has ownership equity of MiraDx.
• Lilie Lin, MD, FASTRO, is employed by University of Texas MD Anderson Cancer Center. Dr. Lin receives grant/research funding from AstraZeneca, Pfizer and Varian. 
• Sean McBride, MD, MPH, is employed by Memorial Sloan Kettering Cancer Center and has no relevant financial relationships to disclose. 
• Andrea Ng, MD, MPH, FASTRO, is employed by Massachusetts General Brigham and has no relevant financial relationships to disclose. 
• Nitin Ohri, MD, MS, is employed by Albert Einstein College of Medicine, Montefiore Medical Center. Dr. Ohri receives grant/research funding from AstraZeneca, Regeneron and Koneksa. Dr. Ohri serves an uncompensated role as principal investigator on studies with Shanghai Henlius Biotech and BeOne Medicines.    
• Ravi Patel, MD, PhD, is employed by University of Pittsburgh Hillman Cancer Center. Dr. Patel receives grant/research funding from Voximetry and Merck. Dr. Patel received compensation/payment from GE Healthcare [relationship ended 11/6/2025].
• Neil K. Taunk, MD, MSCTS, is employed by University of Pennsylvania. Dr. Taunk receives grant/research funding from Point BioPharma/Eli Lilly and Varian Medical Systems. Dr. Taunk receives compensation/payment from Boston Scientific and Point BioPharma/Eli Lilly. Dr. Taunk receives honoraria from Novartis, GE Healthcare, Boston Scientific and Point BioPharma/Eli Lilly. 
• Emi Yoshida, MD, is employed by University of California San Francisco. Dr. Yoshida received honoraria from Merck [relationship ended 6/26/2025]. 
• Nicholas Zaorsky, MD, MS, is employed by University Hospitals and has no relevant financial relationships to disclose. 

Planner/Moderator Disclosures

• Megan Daly, MD, is employed by University of California Davis. Dr. Daly receives grant/research funding from Merck and Genentech. Dr. Daly previously received honoraria from AstraZeneca [relationship ended 12/2025].
• Sue Yom, MD, PhD, FASTRO, is employed by University of California San Francisco. Dr. Yom receives grant/research funding from EMD Serono and Johnson & Johnson.  

Reviewer Disclosure

• Michael Haddock, MD is employed by Mayo Clinic and has no relevant financial relationships to disclose.